表紙
市場調查報告書

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析

Glucokinase - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 364838
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析 Glucokinase - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 60 Pages
簡介

本報告提供以葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的概要

治療藥的開發

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各開發階段

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各治療範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各適應症

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :企業開發中的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的治療藥開發企業

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • Hua Medicine (Shanghai) Ltd.
  • LG Life Science LTD.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Poxel SA
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • vTv Therapeutics Inc
  • Yuhan Corporation

藥物簡介

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :暫停中的計劃

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中止的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2096TDB

Summary

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Diabetes, Obesity and Type 1 Diabetes (Juvenile Diabetes).

The latest report Glucokinase - Pipeline Review, H2 2019, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
  • Eli Lilly and Co
  • Hua Medicine Shanghai Ltd
  • Ligand Pharmaceuticals Inc
  • Merck & Co Inc
  • Pfizer Inc
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Teijin Pharma Ltd
  • vTv Therapeutics Inc
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
  • dorzagliatin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-2608204 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-04937319 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMG-123 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TTP-399 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 25, 2019: Hua Medicine's global first-in-class drug was presented at 2019 Scientific Meeting of CDS
  • Nov 11, 2019: Hua Medicine's pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
  • Nov 08, 2019: Hua Medicine to release phase III 24-weeks topline data of Dorzagliatin monotherapy trial (HMM0301) on November 12
  • Oct 03, 2019: vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
  • Sep 18, 2019: vTv Therapeutics presents additional positive data from the phase 2 Simplici-T1 study in patients with type 1 diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
  • Aug 30, 2019: Hua Medicine completes patient enrollment for Phase III combination with metformin trial of dorzagliatin
  • Jun 06, 2019: vTv Therapeutics announces positive topline results from part 1 of the Phase 2 Simplici-T1 trial in patients with Type 1 Diabetes
  • Jun 04, 2019: Hua Medicine - Business & Pipeline Update
  • Apr 23, 2019: Hua Medicine initiates first combination study of Dorzagliatin with SGLT-2 in the United States
  • Mar 01, 2019: Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin
  • Jan 31, 2019: Hua Medicine initiates first combination study of Dorzagliatin with a DPP-4 inhibitor in the United States
  • Jan 16, 2019: vTv Therapeutics announces publication of comprehensive data in Science Translational Medicine detailing the discovery and clinical development of TTP399, including results of phase 2 AGATA study
  • Jun 22, 2018: vTv Therapeutics to Present a Poster at the American Diabetes Association's 78th Scientific Sessions
  • Mar 22, 2018: vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
  • Nov 08, 2017: vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Hua Medicine Shanghai Ltd, H2 2019
  • Pipeline by Ligand Pharmaceuticals Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
  • Pipeline by Teijin Pharma Ltd, H2 2019
  • Pipeline by vTv Therapeutics Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top